Photothermal antimicrobial therapy within the second near-infrared biological window (NIR-II, 1000–1350 nm) enables improved laser penetration depth and higher maximum permissible exposure (MPE); however, NIR-II photothermal agents (PTAs) with a high photothermal conversion efficiency (PTCE) and superior safety for this purpose remain scarce. Given the inherent merits of conjugated polymers such as excellent biocompatibility, strong light-harvesting ability, and easily tunable spectral properties, a NIR-II PTA based on a donor (D)–acceptor (A) alternating conjugated polymer, namely, poly[4,9-(6,7-bis(4-((2-octyldodecyl)oxy)phenyl)-[1,2,5]thiadiazolo[3,4- g ]quinoxaline)- alt -2,5-(thiophene)] (PTTQ), has been developed for efficient photothermal antimicrobial therapy in vitro and in vivo. PTTQ/amphiphilic polymer (DSPE-MPEG2000) composite nanoparticles (PTTQNPs) exhibit robust absorption in the NIR-II region and an outstanding PTCE of 51.7% upon irradiation with a 1064 nm laser (1 W cm –2 ). With excellent biocompatibility and remarkable photothermal/photo stability, PTTQNPs demonstrated an antibacterial rate of approximately 100% against both Staphylococcus aureus ( S. aureus ) and Escherichia coli ( E. coli ) in vitro and enabled the wounds induced by S. aureus in mice to heal almost completely. This study underscores the potential of D–A alternating conjugated polymers as NIR-II PTAs in the fight against bacterial infections while also providing valuable insights into the structural design of highly efficient NIR-II PTAs based on conjugated polymers.